摘要目的 探讨IFNα治疗慢性肝炎期间甲状腺功能异常情况及其临床特点.方法 对310例应用IFNα治疗的慢性肝炎患者的甲状腺功能进行评估.结果 治疗前,所有患者的血清游离三碘甲状腺原氨酸(FT3)、游离甲状腺素(FT4)、敏感促甲状腺素(sTSH)均正常,甲状腺球蛋白抗体(TGAb)阴性;应用IFNα治疗后,10例(10/310,3.22%)患者出现甲状腺功能异常,其中7例患者血清生化学改变符合甲状腺功能减退症,3例患者符合甲状腺功能亢进症.随访1年后,所有患者的甲状腺功能恢复正常.结论 IFNα治疗慢性肝炎过程中可诱发甲状腺功能异常,采取相应治疗措施后预后良好.

abstractsObjective To investigate the prevalence and clinical characteristics of thyroid dysfunction induced by IFNα therapy in patients with chronic hepatitis.Methods Thyroid function of 310 patients with chronic hepatitis receiving IFNα therapy were evaluated.Results Serum free tri-iodothymnine (F13),free thyroxine(FT4)and sensitive thyroid-stimulating hormone(sTSH)of all patients were normal and TGAb was negative before IFNα therapy.After the treatment,10 patients(10/3 10,3.22%)had thyroid dysfunction,in which 7 were of hypothyroidism and 3 were of hyperthyroidism.The thyroid function of all patients recovered within 1-year follow-up.Conclusions IFNα therapy may induce thyroid dysfunction in patients with chronic hepatitis,in which prognosis can be good when appropriate treatment is given.